Sonilo and Shutterstock are betting that licensed training data could define the future of AI music.
Updated
May 13, 2026 3:39 PM

A human operating a digital turntable. PHOTO: UNSPLASH
As copyright disputes continue to grow around AI-generated music, Sonilo, the world’s first professionally licensed video-to-music AI platform, has partnered with Shutterstock to train its models on licensed music catalogs.
The agreement gives Sonilo access to Shutterstock’s music library for AI model training. According to the companies, it is Shutterstock’s first partnership with a video-to-music AI platform and the timing is significant. AI music companies are facing growing pressure over how their systems are trained. Artists and record labels have increasingly challenged the use of copyrighted music in AI datasets, especially when licensing agreements or compensation structures are unclear.
That tension has created a divide across the industry. Some companies have continued building models around scraped or disputed data. Others are trying to position licensing as part of the product itself.
Sonilo falls into the second group. The company says its models are trained only on licensed material where artists and rights holders have agreed to participate and receive compensation. The Shutterstock partnership strengthens that position while giving Sonilo access to a larger pool of commercially cleared music.
The collaboration also points to a broader change happening inside generative AI. As AI tools move into commercial production, companies are being pushed to show not just what their models can generate, but also where their training data comes from.
Sonilo’s platform is built around video rather than text prompts. The system analyses footage directly, studies pacing and emotional tone, then generates an original soundtrack to match the content. The company says this removes the need for manual music searches, syncing or editing workflows. The generated tracks are cleared for commercial use across social media, branded content and broadcast production.
Shawn Song, CEO of Sonilo, said: "Music has always been the last unsolved layer of video creation, and video has always carried its own soundtrack. We built Sonilo to hear it and compose from it, without a single text prompt. But how we build matters as much as what we build. While others have chosen to take artists' work without permission and charge creators for the privilege, we've chosen a different path—one where artists are compensated from day one. Partnering with Shutterstock reflects that standard. Every model we train meets a bar the music industry can stand behind, because the most innovative AI platforms don't have to come at the expense of the artists who make all of these possible."
For Shutterstock, the deal expands the company’s growing role in generative AI infrastructure. The company has increasingly focused on licensing content for AI systems across images, video and music.
Jessica April, Vice President of Data Licensing & AI Services at Shutterstock, said: "AI innovation depends on access to high-quality, rights-cleared content and trusted licensing partnerships. Sonilo's approach reflects the growing demand for responsibly sourced training data and commercially safe AI workflows. We're pleased to support companies building generative AI products with licensed content and scalable data solutions that help accelerate innovation while respecting creators and rights holders."
The partnership also comes as Sonilo expands into creator and developer ecosystems. Earlier this month, the company launched as a native node inside ComfyUI, an open-source AI workflow platform used by millions of creators. Sonilo also offers API access for integration into creator tools, video platforms, game engines and other AI systems.
As AI-generated music becomes more common across advertising, creator platforms and digital media, the industry’s focus is shifting beyond generation alone. Questions around licensing, ownership and compensation are increasingly shaping how AI music companies position themselves and build trust with creators.
Keep Reading
A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
May 1, 2026 2:25 PM

Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.